Theseus Pharmaceuticals Inc
(NAS:THRX)
$
4.06
0 (0%)
Market Cap: 181.28 Mil
Enterprise Value: -20.19 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 24/100 Theseus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022 / 08:30PM GMT
Release Date Price:
$6.01
(+5.81%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
(technical difficulty) , one of the biotech analysts at Jefferies. And I'm happy to introduce our guest today, Tim Clackson, who is the CEO of Theseus. Thanks so much for joining us today, Tim.
Timothy P. Clackson
Theseus Pharmaceuticals, Inc. - CEO, President & Director
It's a pleasure to be here, Maury.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So maybe for those who may be new to the story, if you can provide a 1-minute intro to Theseus.
Timothy P. Clackson
Theseus Pharmaceuticals, Inc. - CEO, President & Director
Happy to. So Theseus is a pure precision oncology company. And we're focusing on one particular kind of TKI that we think is crucial for success. And that is what we call a covariant inhibitor. That's an inhibitor that's able to inhibit any of the resistance mutations that occur on a oncogenic
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot